Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TNhYP218 CAR T Cells in Mesothelin-Expressing Solid Tumors
NCT06885697Phase 1Recruiting
- Sponsor
- National Cancer Institute
- Start
- Jul 2025
- Primary completion
- Jun 2034
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of hYP218 CAR-T in mesothelioma and solid tumor (2 arms), sponsored by National Cancer Institute. Primary endpoints: Recommended Phase 2 Dose at Week 4 and Objective Response Rate at Week 108. Started Jul 2025; status: recruiting.
02
Drugs
hYP218 CAR-T
03
Conditions
mesotheliomasolid tumor
Beyond the preview
Go deeper on NCT06885697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06885697.